Session » Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1813

Clinical Characteristics & Outcomes Associate with Work Productivity in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study

8:30AM-10:30AM: Abstract Number: 1802

Comparison of Axial and Peripheral Manifestations in Patients with Psoriatic Arthritis and Ankylosing Spondylitis in Upadacitinib Clinical Trials

8:30AM-10:30AM: Abstract Number: 1817

Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1

8:30AM-10:30AM: Abstract Number: 1812

Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program

8:30AM-10:30AM: Abstract Number: 1810

Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA)

8:30AM-10:30AM: Abstract Number: 1806

Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition

8:30AM-10:30AM: Abstract Number: 1830

Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis

8:30AM-10:30AM: Abstract Number: 1820

Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

8:30AM-10:30AM: Abstract Number: 1811

Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies

8:30AM-10:30AM: Abstract Number: 1809

Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 1823

Efficacy of Upadacitinib in Patients with Active Psoriatic Arthritis and a Low or High Swollen Joint Count: A Subgroup Analysis of 2 Phase 3 Studies

8:30AM-10:30AM: Abstract Number: 1808

Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial

8:30AM-10:30AM: Abstract Number: 1803

Long-term Safety of Guselkumab (TREMFYA®) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years

8:30AM-10:30AM: Abstract Number: 1805

Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 1814

Patient Characteristics and Clinical Features Associate with Health-Related Quality of Life in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study

8:30AM-10:30AM: Abstract Number: 1829

Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options

8:30AM-10:30AM: Abstract Number: 1831

Predictors of Response, Adverse Events and Treatment Retention in Psoriatic Arthritis Patients Treated with Golimumab in a Prospective, Observational Registry

8:30AM-10:30AM: Abstract Number: 1827

Psoriatic Arthritis, Female Sex and Increased Baseline Skin Severity Are Associated with Drug Persistence in Ustekinumab-Treated Patients with Psoriasis in the BADBIR Cohort

8:30AM-10:30AM: Abstract Number: 1815

Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis

8:30AM-10:30AM: Abstract Number: 1818

Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

8:30AM-10:30AM: Abstract Number: 1826

Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 1822

Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

8:30AM-10:30AM: Abstract Number: 1807

Relationships Between Fatigue and Hemoglobin/C-Reactive Protein Levels and Associations Between Fatigue and Clinical Response in Patients with Active Psoriatic Arthritis: Results from Two Randomized Controlled Trials of Guselkumab (TREMFYA®)

8:30AM-10:30AM: Abstract Number: 1833

Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis

8:30AM-10:30AM: Abstract Number: 1821

Role of Patient Organizations in Implementation of Recommended Non-pharmacological Treatment Modalities in Spondyloarthritis: Evidence for the Effectiveness of Self-management Strategies

8:30AM-10:30AM: Abstract Number: 1828

Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis

8:30AM-10:30AM: Abstract Number: 1835

Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies

8:30AM-10:30AM: Abstract Number: 1825

Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies

8:30AM-10:30AM: Abstract Number: 1832

Secukinumab Therapy in Biologic-naïve vs. Biologic-experienced Patients: Real-world Effectiveness, Persistence and Safety Results from the Rheumatic Diseases Portuguese Registry

8:30AM-10:30AM: Abstract Number: 1824

Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study

8:30AM-10:30AM: Abstract Number: 1804

Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis

8:30AM-10:30AM: Abstract Number: 1801

The Effect of Ixekizumab versus Adalimumab on Individual Components of the ACR Composite Score, with and Without Concomitant Methotrexate or Other Conventional Synthetic DMARDs at 52 Weeks in Patients with Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 1819

Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metabolic Syndrome Status

8:30AM-10:30AM: Abstract Number: 1834

To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population

8:30AM-10:30AM: Abstract Number: 1816

Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].